NEW YORK (GenomeWeb News) – SynapDx announced this week that Kevin Hrusovsky has joined the firm's board of directors. He most recently served as president of life sciences and technology at PerkinElmer. Hrusovsky had been CEO of Caliper Life Sciences from 2003 to 2011, when the firm was purchased by PerkinElmer for more than $600 million. He left PerkinElmer earlier this year but agreed to serve as a consultant for up to one year. He also serves on the board of directors of 908 Devices.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.